



**Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting  
November 5, 2008**

**Location: Iowa State Capitol Building  
Room 116  
Des Moines, Iowa 50319**

**Time: 9:30 a.m. – 1:30 p.m.**

**Final Agenda**

1. Welcome & Introductions
  - a) Commission Members and Staff
  - b) Approval of the minutes
2. Iowa Medicaid Enterprise Update(s)
3. Case Reviews
4. Management Reports for Quarter 1 - State Fiscal Year 2008-09
5. Smoking Cessation Report for Legislature – Review final version
6. Pro-DUR Edits
  - a) Glucagen – Recommend 5/30 to mirror current edit for Glucagon Emergency Kit
7. Focus Studies/Provider Education Initiatives
  - a) Under Utilization of Corticosteroids – UPDATE: Review of medical claims data
  - b) Quarterly Narcotic Utilization Report to Prescribers – Additional discussion
  - c) Chronic Singulair Use without Asthma or Allergic Rhinitis Diagnosis – Add'l data
  - d) Long Term Gastric Acid Suppressive Drug Use and Risks of Pneumonia and *Clostridium difficile* – Initial Data Review
8. Public Comment
9. Prior Authorization
  - a) Vusion™ Ointment – Review comments and final recommendation
  - b) Growth Hormone – Excluding coverage for Idiopathic Short Stature; review comments, prescribers data, final recommendation
  - c) Linezolid (Zyvox®) – Verbiage adjustment; review comments, final recommendation
  - d) Serotonin 5-HT<sub>1</sub>-receptor Agonists – Adjustment of quantity allowed per month without PA; review comments, final recommendation
  - e) Extended Release Formulation – Add Luvox CR; review comments, final recommendation

10. Public Comment
11. Miscellaneous
  - a) DUR Digest – 2008 Vol. 21 No. 1: Update
  - b) MedWatch
12. Executive Closed Session
  - a) Approval of Minutes
  - b) Member Profiles
13. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

**[www.iadur.org](http://www.iadur.org)**

For more information contact the DUR Director, Chad Bissell, Pharm.D. at [info@iadur.org](mailto:info@iadur.org) or (515) 725-1271